Plaintiffs in pharmaceutical and other biomedical litigation have frequently resorted to allegations of “ghostwriting” to attack various a
Continue Reading Senator Writes Letter To NIH About “Ghostwriting”
Defense of Mass Tort Claims, Class Actions, and Significant Product-Based Litigation
Plaintiffs in pharmaceutical and other biomedical litigation have frequently resorted to allegations of “ghostwriting” to attack various a…
Continue Reading Senator Writes Letter To NIH About “Ghostwriting”